Metastatic melanoma to the brain is a difficult and frequent clinical challenge. Current systemic treatments for patients with melanoma and brain involvement are limited and largely ineffective.
INTRODUCTION
Malignant melanoma commonly metastasizes to the brain and it has been estimated that up to 75% of patients with metastatic melanoma ultimately develop brain metastases. 1 Because current systemic treatments for brain metastases are limited and largely ineffective, these patients have a poor prognosis. Current strategies include supportive care, surgical resection, stereotactic radiosurgery, whole brain radiation, chemotherapy, or combinations of these agents. Resection 2 and radiosurgery 22 can produce effective palliation in selected cases, but this is usually restricted to patients with few lesions. Radiation therapy is the current standard of care for individuals with multiple brain metastases; it can improve neurologic symptoms but does not alter survival.
Tumor regression has been observed at all visceral and soft tissue sites including brain. Because TIL cannot be generated for all patients, we have also investigated the infusion of peripheral blood lymphocytes that were transduced with retroviral vectors to express a T-cell receptor that recognized either gp-100 or MART-1 in HLA-A2+ patients. 8 The objective response rates for these trials have been reported to be 20-30% and durable tumor regression at all disease sites including brain has also been observed. 8, 9 Typically 4 to 6 weeks of cell culture are required to obtain adequate numbers of reactive lymphocytes for any of our clinical protocols. As a consequence, there may be a 6 to 8 week interval between the screening brain MRI evaluation that was generally obtained by the referring oncologist and the protocol baseline images obtained immediately prior to the start of chemotherapy. The majority of patients in this report developed brain metastases during this short interval.
PATIENTS AND METHODS
Between 2000 and 2009, 264 patients with metastatic melanoma were enrolled on one of a series of sequential trials designed to investigate ACT with TIL or TCR and high dose IL-2 along with a nonmyeloablating conditioning regimen. All patients had measurable metastatic extracranial disease are noted in Tables 1 and 2 .
Conditioning regimen
The conditioning regimens have been previously described in detail.
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In brief, the regimen consisted of cyclophosphamide (60mg/kg/day on days -7 and -6) and fludarabine (25mg/m 2 /day on days -5 to -1). In some protocols additional lymphodepletion with 2-Gy, 6-Gy, or 12-Gy was added over the 1 to 3 days immediately prior to cell transfer and chemotherapy was compressed, overlapping the two agents. Patients received the lymphocyte infusion on day 0 along with IL-2 (720,000 IU/kg q8hr) as tolerated to a maximum of 15 doses. Platelet counts were generally maintained by transfusion at > 20,000/µl for patients with known brain metastases. Patients were re-evaluated at all known tumor sites including the brain approximately 4 to 6 weeks after the initiation of treatment and subsequently at 4 to 8 week intervals.
Cell Products used for therapy
Patients received an autologous lymphocyte product manufactured in the Surgery Branch Cell Production Facility that passed a protocol-specific certificate of analysis including potency, safety, and sterility criteria. Patients listed in Table 1 Briefly, resected specimens were enzymatically disaggregated into single cell suspensions or small tumor fragments were separated and plated to initiate cultures. TIL were propagated in 6000 IU/ml IL-2 in complete media containing 10% human serum until a homogenous lymphocyte culture evolved. Some cultures (patients 1-4 and 13, "TIL", Table 1) were highly selected by assessing tumor recognition and other cultures were grown from the entire cell population and were (patients 9-12, 15-17, "CD8 YT", Patients listed in Table 2 ; and HLA-A2/gp100:154-162 specific "g154"
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STATISTICAL ANALYSIS
Objective response rates (partial and complete), duration of response and time to progression (time from treatment to disease progression) were calculated and overall survival probabilities (treatment to last follow-up or death) were estimated using the Kaplan-Meier
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Although the brain metastases were small (< 10 mm), standard RECIST criteria for response was also used to evaluate the in brain response but ultimately no partial responses were encountered. The duration of response was determined from the date patients received the cell infusion.
RESULTS

In Brain Response and Overall Response to TIL
Seventeen patients that received TIL with a lymphodepleting preparative regimen and 
DISCUSSION
The treatment of brain metastases from melanoma remains a difficult clinical challenge.
The prognosis for patients with brain metastases is poor, with the median survival ranging from
on The management of these patients is complicated by the need to treat both the CNS metastases as well as the other systemic disease.
Resection or stereotactic radiosurgery of solitary melanoma brain metastases either with or without whole brain radiation therapy (WBRT) is recognized as the treatment of choice.
Retrospective surgical series suggest that the median survival for patients with resected solitary lesions is approximately 5 to 8 months.
2,18,19
Retrospective series using WBRT after surgical resection in patients with melanoma brain metastases report no survival benefit.
2,20,21
The results with stereotactic radiosurgery appear to be comparable to resection with a median survival for patients with solitary and multiple brain metastases ranging from 5 to 9 months. 22 WBRT in concert with radiosurgery appears to prevent new lesions and neurologic causes of death but has no impact on survival largely due to uncontrolled extracranial disease. 23 Conversely, chemotherapy alone has been largely unsuccessful in treating melanoma brain metastases. A multicenter Phase II study of temozolomide in 151 patients with brain metastases from melanoma reported a 7% response rate in the brain with a median survival of 3.5 months. 4 Similarly, immunotherapy with high dose bolus IL-2 has also been ineffective. One retrospective study at the National Cancer Institute reported an overall response rate of 5.6% for patients with previously untreated brain metastases. Two of thirty-six patients with evaluable brain metastases had objective regression of intracranial and extracranial disease after receiving IL-2. 5 Ipilimumab has recently been reported to cause the complete regression of untreated melanoma brain metastases in two patients. 24, 25 A phase II trial that investigated the treatment of melanoma brain metastases with ipilimumab reported that in 51 patients with melanoma brain metastases, 5
patients developed a partial response in the brain. Our patients were carefully selected and we treated only patients with brain lesions < 10 mm that had no evidence of significant edema, mass effect, or symptoms prior to cell therapy.
The largest lesion that responded to this therapy was 10 mm. The response rate of larger lesions to this treatment approach is unknown but needs to be investigated. Interestingly, all of the intracranial tumor regressions were complete. In addition, 7 of the 9 patients that responded in the brain also achieved an objective response overall. Conversely, all patients that failed to achieve a response in the brain also failed to achieve an overall objective response at other visceral sites. This fact suggests that brain metastases are as responsive to ACT as extracranial sites. Moreover, it confirms that activated lymphocytes can effectively traffic to the central nervous system (CNS).
on ACT with autologous antitumor lymphocytes plus high dose IL-2 following a lymphodepleting preparative regimen can mediate complete and durable regression of metastatic melanoma in the brain and can result in long term survival. Furthermore, this therapy is safe in selected patients so that the presence of melanoma brain metastases is not necessarily a contraindication to ACT therapy. These results demonstrate that ACT is unique in its ability to achieve high objective response rates at both intracranial and extracranial sites and many of these responses appear to be durable. 
